ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      6,101.24
      -0.29%
      US Tech 100
      21,156.80
      -0.70%
      Dow Jones
      44,424.25
      -0.32%
      Brent Oil
      77.625
      0.00%
      Bitcoin
      104,608.50
      -0.12%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Bicara Therapeutics Inc (BCAX) Quote

      Bicara Therapeutics Inc

      Bicara Therapeutics Inc (BCAX)

      NASDAQ
      11.605
      -0.365
      (-3.05%)
      Closed January 26 4:00PM
      Delayed by 15 minutes
      11.605
      0.00
      (0.00%)
      After Hours: 6:55PM
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      Key stats and details

      Current Price
      11.605
      Bid
      11.50
      Ask
      12.16
      Volume
      322,007
      11.55 Day's Range 12.325
      11.51 52 Week Range 28.09
      Market Cap
      631.493M
      Previous Close
      11.97
      Open
      12.03
      Last Trade
      2
      @
      12.15
      Last Trade Time
      Financial Volume
      $ 3,825,876
      VWAP
      11.8813
      Average Volume (3m)
      433,514
      Shares Outstanding
      54,415,619
      Dividend Yield
      -
      PE Ratio
      -12.14
      Earnings Per Share (EPS)
      -0.96
      Revenue
      -
      Net Profit
      -51.99M

      About Bicara Therapeutics Inc

      Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Our lead program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor... Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Our lead program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, or HNSCC, where there remains a significant unmet need. We intend to initiate a pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab as a first-line therapy in recurrent/metastatic HNSCC excluding HPV-positive patients with oropharyngeal squamous cell carcinoma late in the fourth quarter of 2024 or early in the first quarter of 2025. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.bicara.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Bicara Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker BCAX. The last closing price for Bicara Therapeutics was $11.97. Over the last year, Bicara Therapeutics shares have traded in a share price range of $ 11.51 to $ 28.09.

      Bicara Therapeutics currently has 54,415,619 shares outstanding. The market capitalization of Bicara Therapeutics is $651.35 million. Bicara Therapeutics has a price to earnings ratio (PE ratio) of -12.14.

      Ask ADVFN Intelligence (AI)

      BCAX Latest News

      More News

      Form 8-K - Current report

      January 13 2025
      Edgar (US Regulatory)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      November 12 2024
      Edgar (US Regulatory)

      Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

      On track to initiate FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Completed upsized initial public offering, raising approximately $362 million in gross proceeds...

      November 12 2024
      GlobeNewswire Inc.

      Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference

      BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for...

      November 11 2024
      GlobeNewswire Inc.

      Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

      BOSTON, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for...

      September 16 2024
      GlobeNewswire Inc.

      Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering

      BOSTON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to...

      September 12 2024
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.405-3.372189841812.0112.48511.5128620612.03699428CS
      4-7.5642-39.460175698519.169219.2211.5136242714.4777588CS
      12-12.235-51.321308724823.8428.0911.5143351418.033026CS
      26-14.645-55.790476190526.2528.0911.5142753419.93975555CS
      52-14.645-55.790476190526.2528.0911.5142753419.93975555CS
      156-14.645-55.790476190526.2528.0911.5142753419.93975555CS
      260-14.645-55.790476190526.2528.0911.5142753419.93975555CS

      BCAX - Frequently Asked Questions (FAQ)

      What is the current Bicara Therapeutics share price?
      The current share price of Bicara Therapeutics is $ 11.605
      How many Bicara Therapeutics shares are in issue?
      Bicara Therapeutics has 54,415,619 shares in issue
      What is the market cap of Bicara Therapeutics?
      The market capitalisation of Bicara Therapeutics is USD 651.35M
      What is the 1 year trading range for Bicara Therapeutics share price?
      Bicara Therapeutics has traded in the range of $ 11.51 to $ 28.09 during the past year
      What is the PE ratio of Bicara Therapeutics?
      The price to earnings ratio of Bicara Therapeutics is -12.14
      What is the reporting currency for Bicara Therapeutics?
      Bicara Therapeutics reports financial results in USD
      What is the latest annual profit for Bicara Therapeutics?
      The latest annual profit of Bicara Therapeutics is USD -51.99M
      What is the registered address of Bicara Therapeutics?
      The registered address for Bicara Therapeutics is CORPORATION TRUST CENTER, 1209 ORANGE ST, NEW CASTLE, WILMINGTON, DELAWARE, 19801
      What is the Bicara Therapeutics website address?
      The website address for Bicara Therapeutics is www.bicara.com
      Which industry sector does Bicara Therapeutics operate in?
      Bicara Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      NVNINVNI Group Ltd
      $ 4.38
      (193.96%)
      		366.98M
      EVAXEvaxion Biotech AS
      $ 5.99
      (64.56%)
      		55.41M
      ELABPMGC Holdings Inc
      $ 3.0901
      (56.07%)
      		76.48M
      PCLAPicoCELA Inc
      $ 4.60
      (49.35%)
      		3.75M
      GOEVCanoo Inc
      $ 0.475
      (43.94%)
      		282.22M
      GODNUGolden Star Acquisition Corporation
      $ 3.11
      (-75.82%)
      		17.51k
      GODNGolden Star Acquisition Corporation
      $ 2.93
      (-65.67%)
      		902.76k
      NXTTNext Technology Holding Inc
      $ 1.37
      (-54.93%)
      		2.56M
      SGLYSingularity Future Technology Ltd
      $ 1.625
      (-38.45%)
      		917.77k
      WHLRLWheeler Real Estate Investment Trust Inc
      $ 90.11
      (-38.07%)
      		8
      ACONAclarion Inc
      $ 0.0557
      (28.94%)
      		811.91M
      NVNINVNI Group Ltd
      $ 4.38
      (193.96%)
      		366.98M
      RIMEAlgorhythm Holdings Inc
      $ 0.0357
      (4.69%)
      		284.97M
      GOEVCanoo Inc
      $ 0.475
      (43.94%)
      		282.22M
      NVDANVIDIA Corporation
      $ 142.62
      (-3.12%)
      		232.88M

      Discussion

      View Full Feed
      Gmenfan Gmenfan 4 minutes ago
      How much are second hand parachutes? And I'm being kind here.....
      igotthemojo igotthemojo 5 minutes ago
      i told you the last time you made that comment about yarn that it was stupid...and then you repeated the same nonsense...

      you were DEAD WRONG then and you are DEAD WRONG now...

      "And yes, we know, "this time is different"."

      FINALLY you have stated somethin
      KBLB
      ilovetech ilovetech 5 minutes ago
      If I were the CEO of NWBO, I would SERIOUSLY consider the block chain dividend strategy, which Danish posted about on X. That is unless LP has decided to go with a merger, for example, with a company like Revimmune to register under a new CUSP number, where both strategies have successfully squeeze
      NWBO
      Airfred Airfred 6 minutes ago
      Love the idea I’ll sign

      Long time reader first time writing
      FNMA
      Pnypnchr Pnypnchr 7 minutes ago
      This is ihub, that will never change me.
      BLTHD
      Investor2014 Investor2014 7 minutes ago
      Exactly, a correlation to actual endpoints of the trial must be established.
      It also has yet to be shown to be correlated with or causative of clinical outcomes.

      From there further trials would be needed, where brain atrophy reduction is confirmed correlated to cognitive and/or
      AVXL
      MightyX MightyX 8 minutes ago
      Your homies allow-you to f-bomb..good show for-the public
      TPTW
      georgejjl georgejjl 8 minutes ago
      Pantheon and Syntagon combined give Anavex the production process control and capacity to produce Blarcamesine for commercialization and worldwide distribution and sales.

      https://patheon.com/

      https://www.syntegon.com/company

      Good luck and GOD bless,
      AVXL
      PEACHMAN PEACHMAN 8 minutes ago
      Plenty of accurate due diligence and news available at IFUS website

      https://impactfusionbrands.com/news/

      IFUS STRONG
      IFUS
      StayHumble StayHumble 9 minutes ago
      Update!💹FundersWait✅2Ensure $DBMM Still Trades✅idiot💹

      $DBMM has the Ability to move forward, to continue to grow its business, benefits its shareholders and asks that the Commission affirm the decision of the Law Judge denying revocation of its regis
      DBMM GTII HPIL
      SHEEPWOLF SHEEPWOLF 9 minutes ago
      $ILLR TRILLER GROUP CEO WING FAI NG and Mario Lopez at #BKFC KM5
      https://investorshub.advfn.com/uimage/uploads/2025/1/26/muhlpSmartSelect_20250126_154850_X.jpg
      ILLR
      SHEEPWOLF SHEEPWOLF 10 minutes ago
      $ILLR TRILLER GROUP CEO WING FAI NG and Mario Lopez at #BKFC KM5
      https://investorshub.advfn.com/uimage/uploads/2025/1/26/muhlpSmartSelect_20250126_154850_X.jpg
      ILLR
      doccjc doccjc 10 minutes ago
      style="caret-color: rgb(41, 56, 73); color: rgba(41, 56, 73, 1); font-family: Montserrat, sans-serif; letter-spacing: 0.1px; text-align: justify; background-color: rgba(255, 255, 255, 1)""The study has received regulatory approval to expand to 30 patients, targeting cancerous nodes throughout the bo
      RDGL
      okwife okwife 10 minutes ago
      does it say it will go higher??
      MRJ25 MRJ25 11 minutes ago
      I will be happy to sign. Let me know.
      FNMA
      thistraderknowsall thistraderknowsall 11 minutes ago
      MAJOR BREAKOUT!**** SPELL**** Crypto!!! AI!!
      Nice move up! And now SPELL exponentially moving up to $1 also!!

      CONGRATS!!
      joe botts joe botts 11 minutes ago
      Wow , extra entertaining today. Seriously hysterical.
      PEACHMAN PEACHMAN 11 minutes ago
      IFUS interviews are all available below

      https://impactfusionbrands.com/interviews/


      IFUS STRONG
      IFUS
      JamesF1 JamesF1 12 minutes ago
      I am sure it is NOT being marketed right now. It’s probably ready to go, but it’s not being sold right now.
      ELTP
      Madanthony2 Madanthony2 12 minutes ago
      Ol JB drilled next pebble too, then walked away to start new shell game, thats all this is.
      LBSR
      PEACHMAN PEACHMAN 13 minutes ago
      IFUS Revenues increasing on Intact Nutrition products as new distributors and sales continue

      https://impactfusionbrands.com/products/intact-nutrition/


      IFUS STRONG
      IFUS
      BDEZ BDEZ 13 minutes ago
      Technically no....realistically yes.
      ChannelTrader ChannelTrader 13 minutes ago
      Trump slaps retaliatory measures on Colombia after it turns away deportation flights

      https://www.msn.com/en-us/news/world/trump-slaps-retaliatory-measures-on-colombia-after-it-turns-away-deportation-flights/ar-AA1xTQKF?ocid=winp2fptaskbar&cvid=39577a689f1b407f956e556928addcb9&ei=5
      hedge_fun hedge_fun 13 minutes ago
      I thought closing on Lena was big stuff…….and

      the poster you responded to said everything worked out great.

      https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175700851
      APRU

      Your Recent History

      NASDAQ
      BCAX
      Bicara Therapeutics
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads